Aquestive Therapeutics (NASDAQ:AQST) Announces Earnings Results

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07), Zacks reports. The business had revenue of $8.72 million for the quarter, compared to analyst estimates of $12.23 million. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Stock Performance

NASDAQ AQST remained flat at $2.38 on Friday. 2,580,850 shares of the company's stock traded hands, compared to its average volume of 1,508,895. The stock's fifty day simple moving average is $2.76 and its 200-day simple moving average is $3.36. The company has a market capitalization of $236.38 million, a price-to-earnings ratio of -5.29 and a beta of 2.02. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80.

Institutional Trading of Aquestive Therapeutics

A hedge fund recently raised its stake in Aquestive Therapeutics stock. AQR Capital Management LLC grew its stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 12.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 129,019 shares of the company's stock after buying an additional 14,025 shares during the period. AQR Capital Management LLC owned 0.13% of Aquestive Therapeutics worth $374,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 32.45% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. Alliance Global Partners restated a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Thursday. Finally, Lake Street Capital cut their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, March 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $10.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.